It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
SETBP1 variants occur as somatic mutations in several hematological malignancies such as atypical chronic myeloid leukemia and as de novo germline mutations in the Schinzel–Giedion syndrome. Here we show that SETBP1 binds to gDNA in AT-rich promoter regions, causing activation of gene expression through recruitment of a HCF1/KMT2A/PHF8 epigenetic complex. Deletion of two AT-hooks abrogates the binding of SETBP1 to gDNA and impairs target gene upregulation. Genes controlled by SETBP1 such as MECOM are significantly upregulated in leukemias containing SETBP1 mutations. Gene ontology analysis of deregulated SETBP1 target genes indicates that they are also key controllers of visceral organ development and brain morphogenesis. In line with these findings, in utero brain electroporation of mutated SETBP1 causes impairment of mouse neurogenesis with a profound delay in neuronal migration. In summary, this work unveils a SETBP1 function that directly affects gene transcription and clarifies the mechanism operating in myeloid malignancies and in the Schinzel–Giedion syndrome caused by SETBP1 mutations.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Department of Medicine and Surgery, University of Milano-Bicocca and San Gerardo hospital, Monza, Italy
2 Stem Cell and Neurogenesis Unit, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy
3 Department of Biochemistry and Developmental Biology, Faculty of Medicine, Meilahti Clinical Proteomics Core Facility, University of Helsinki, Helsinki, Finland
4 Service d’Hématologie Adulte, Hôpital Saint-Louis, Paris, France
5 Chair and Hematology Section, Ferrarotto Hospital, AOU Policlinico, Catania, Italy
6 Azienda Brotzu U.O. Ematologia e CTMO, Ospedale Businco, Cagliari, Italy
7 UO Ematologia Azienda Ospedaliera “BIANCHI MELACRINO MORELLI”, Reggio Calabria, Italy
8 Dipartimento Medicina Clinica e Sperimentale, Università Insubria, Varese, Italy
9 Division of Hematology, University Hospital Ospedale di Circolo e Fondazione Macchi, Varese, Italy
10 Hematology, Dipartimento di Medicina Clinica e Sperimentale, University of Varese, Varese, Italy
11 BMT Center - Oncohematology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
12 Department of Clinical and Biological Sciences, University of Torino, Orbassano (Torino), Italy
13 Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
14 Oncology Unit, ASST Valle Olona, Ospedale di Circolo di Busto Arsizio, Busto Arsizio, Italy
15 Stem Cell and Neurogenesis Unit, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy; CNR Institute of Neuroscience, Milan, Italy